Bernstein David I, Biagini Raymond E, Karnani Ravi, Hamilton Robert, Murphy Karen, Bernstein Cheryl, Arif Siti Arija M, Berendts Brian, Yeang H Y
University of Cincinnati College of Medicine, Ohio, USA.
J Allergy Clin Immunol. 2003 Mar;111(3):610-6. doi: 10.1067/mai.2003.164.
Thirteen proteins of natural rubber latex (Hevea brasiliensis) known to bind human IgE have been isolated and characterized as Hev b allergens. However, the in vivo importance of native Hev b allergens has not been defined in health care workers (HCWs) with natural rubber latex (NRL) allergy.
The principal aim of this study was to identify the major in vivo Hev b allergens in HCWs with NRL allergy confirmed by percutaneous sensitivity to nonammoniated latex (NAL).
Skin prick testing was performed with 7 (native) proteins purified from NAL (Hev b 1, 2, 3, 4, 6.01, 7.01, and a newly described Hev b 13) and recombinant Hev b 5 in 62 HCWs with histories of NRL allergy (group 1) confirmed by percutaneous reactivity to NAL and in 49 atopic HCWs without NRL allergy (group 2). Serial 10-fold concentrations of Hev b proteins (5 x 10(-5) microg/mL to 50 microg/mL) were tested; serum samples of subjects were assayed for serum specific IgE by immunoassays.
Hev b 2, Hev b 5, Hev b 6.01, and Hev b 13 produced skin reactions in more than 60% of group 1 subjects, with Hev b 1, 3, 4, and 7.01 eliciting reactions in less than 50%. Only 1 of 49 group 2 workers reacted to a single Hev b antigen (Hev b 13). Specificity of 7 Hev b allergens was 100% and 98% for Hev b 13 in identifying workers with confirmed NRL allergy. Specific IgE by AlaSTAT and CAP immunoassays was elevated in 40 of 60 (67%) and 33 of 62 (53%) of NAL-reactive workers and produced false-positive test results in 4 of 49 (8%) and 3 of 48 (6%) group 2 subjects, respectively.
Hev b 2, 5, and 6.01 are major in vivo allergens and Hev b 13 is a new major in vivo allergen among HCWs with allergy to NRL.
已从天然橡胶乳胶(巴西橡胶树)中分离出13种已知可与人IgE结合的蛋白质,并将其鉴定为Hev b过敏原。然而,对于对天然橡胶乳胶(NRL)过敏的医护人员(HCW)而言,天然Hev b过敏原在体内的重要性尚未明确。
本研究的主要目的是在经非氨化乳胶(NAL)经皮敏感性确认对NRL过敏的医护人员中,鉴定主要的体内Hev b过敏原。
用从NAL中纯化的7种(天然)蛋白质(Hev b 1、2、3、4、6.01、7.01和一种新描述的Hev b 13)和重组Hev b 5对62名有NRL过敏史(第1组)的医护人员进行皮肤点刺试验,这些医护人员经对NAL的经皮反应性确认;并对49名无NRL过敏的特应性医护人员(第2组)进行试验。测试了10倍系列浓度的Hev b蛋白(5×10⁻⁵μg/mL至50μg/mL);通过免疫测定法检测受试者的血清样本中的血清特异性IgE。
Hev b 2、Hev b 5、Hev b 6.01和Hev b 13在超过60%的第1组受试者中引起皮肤反应,而Hev b 1、3、4和7.01引起反应的比例低于50%。49名第2组工作人员中只有1人对单一Hev b抗原(Hev b 13)有反应。7种Hev b过敏原在鉴定确诊为NRL过敏的工作人员时,Hev b 13的特异性分别为100%和98%。通过AlaSTAT和CAP免疫测定法检测,60名对NAL有反应的工作人员中有40名(67%)和62名中有33名(53%)的特异性IgE升高,第2组受试者中分别有49名中的4名(8%)和48名中的3名(6%)出现假阳性检测结果。
在对NRL过敏的医护人员中,Hev b 2、5和6.01是主要的体内过敏原,Hev b 13是一种新的主要体内过敏原。